Windtree Therapeutics (WINT) S-1/A 6 May 20 2019 FY IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2019
Document Information [Line Items]
Entity Registrant Name	WINDTREE THERAPEUTICS INC /DE/
Entity Central Index Key	0000946486
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Document Type	S-1/A
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	true
Amendment Description	Amendment 1

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 22,578	$ 11,187
Available-for-sale marketable securities		13,959
Prepaid expenses and other current assets	1,283	507
Total current assets	23,861	25,653
Property and equipment, net	798	802
Restricted cash	154	171
Operating lease right-of-use assets	1,390
Intangible assets	77,090	77,090
Goodwill	15,682	15,682
Total assets	118,975	119,398
Current Liabilities:
Accounts payable	1,708	3,420
Collaboration and device development payable, net	1,972	2,576
Accrued expenses	3,226	6,465
Operating lease liabilities - current portion	750
Deferred revenue - current portion		198
Loans payable - current portion	161	7,974
Total current liabilities	7,817	20,633
Operating lease liabilities - non-current portion	794
Loans payable - non-current portion	4,608
Restructured debt liability - contingent milestone payments	15,000	15,000
Deferred tax liabilities	15,821	15,476
Other liabilities		175
Total liabilities	44,040	51,284
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2019 and December 31, 2018
Common stock, $0.001 par value; 120,000,000 shares authorized at December 31, 2019 and December 31, 2018; 13,697,420 and 10,711,088 shares issued at December 31, 2019 and December 31, 2018, respectively; 13,697,395 shares and 10,711,063 shares outstanding at December 31, 2019 and December 31, 2018, respectively	14	11
Additional paid-in capital	763,097	728,804
Accumulated deficit	(685,122)	(657,647)
Treasury stock (at cost); 25 shares	(3,054)	(3,054)
Total stockholders' equity	74,935	68,114
Total liabilities & stockholders' equity	$ 118,975	$ 119,398

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	13,697,420	10,711,088
Common stock, shares outstanding (in shares)	13,697,395	10,711,063
Treasury stock, shares (in shares)	25	25

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total revenues	$ 198,000	$ 1,788,000
Expenses:
Research and development	12,687,000	10,562,000
General and administrative	12,404,000	7,421,000
Total operating expense	25,091,000	17,983,000
Operating loss	(24,893,000)	(16,195,000)
Other income / (expense):
Net loss on debt extinguishment	(1,794,000)	(3,345,000)
Interest income	153,000	15,000
Interest expense	(495,000)	(1,409,000)
Other (expense) / income, net	(446,000)	401,000
Other expense, net	(2,582,000)	(4,338,000)
Net loss	(27,475,000)	(20,533,000)
AEROSURF warrant dividend		(12,505,000)
Deemed dividend on Series A preferred stock		(1,718,000)
Net loss attributable to common shareholders	$ (27,475,000)	$ (34,756,000)
Net loss per common share Basic and diluted (in dollars per share)	$ (2.51)	$ (23.20)
Weighted average number of common shares outstanding Basic and diluted (in shares)	10,928	1,498
Grant [Member]
License revenue with affiliate		$ 765,000
License [Member]
License revenue with affiliate	$ 198,000	$ 1,023,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Share Purchase Agreement [Member]Preferred Stock [Member]	Share Purchase Agreement [Member]Common Stock [Member]	Share Purchase Agreement [Member]Additional Paid-in Capital [Member]	Share Purchase Agreement [Member]Retained Earnings [Member]	Share Purchase Agreement [Member]Treasury Stock [Member]	Share Purchase Agreement [Member]	Share Purchase Agreement, December 2018 [Member]Preferred Stock [Member]	Share Purchase Agreement, December 2018 [Member]Common Stock [Member]	Share Purchase Agreement, December 2018 [Member]Additional Paid-in Capital [Member]	Share Purchase Agreement, December 2018 [Member]Retained Earnings [Member]	Share Purchase Agreement, December 2018 [Member]Treasury Stock [Member]	Share Purchase Agreement, December 2018 [Member]	Placement Agent [Member]Preferred Stock [Member]	Placement Agent [Member]Common Stock [Member]	Placement Agent [Member]Additional Paid-in Capital [Member]	Placement Agent [Member]Retained Earnings [Member]	Placement Agent [Member]Treasury Stock [Member]	Placement Agent [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Preferred Stock [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Common Stock [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Additional Paid-in Capital [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Retained Earnings [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]Treasury Stock [Member]	Warrants in Connection with Equity Consideration in Debt Issuance [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Preferred Stock [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Common Stock [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Additional Paid-in Capital [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Retained Earnings [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]Treasury Stock [Member]	Warrants in Connection with Equity Consideration in Payable Restructuring [Member]	Placement Agent [Member]Preferred Stock [Member]	Placement Agent [Member]Common Stock [Member]	Placement Agent [Member]Additional Paid-in Capital [Member]	Placement Agent [Member]Retained Earnings [Member]	Placement Agent [Member]Treasury Stock [Member]	Placement Agent [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017																																					3,000	1,075,000
Balance at Dec. 31, 2017																																						$ 1	$ 616,247	$ (637,114)	$ (3,054)	$ (23,920)
Net loss																																								(20,533)		(20,533)
Preferred stock conversions (in shares)																																					(3,000)	45,000
Preferred stock conversions
Issuance of stock (in shares)		181,000						3,929,000						38,000
Issuance of stock			$ 2,541			$ 2,541		$ 4	$ 41,109			$ 41,113
Issuance of common stock, CVie Acquisition (in shares)																																						5,421,000
Issuance of common stock, CVie Acquisition																																						$ 6	67,494			67,500
Vesting of restricted stock units (in shares)																																						32,000
Vesting of restricted stock units
Withholding tax payments related to net share settlements of restricted stock units (in shares)																																						(10,000)
Withholding tax payments related to net share settlements of restricted stock units																																							(155)			(155)
Issuance of warrants																					$ 417			$ 417			$ 196			$ 196
Stock-based compensation expense																																							955			$ 955
Withholding tax payments related to net share settlements of restricted stock units (in shares)																																						10,000
Balance (in shares) at Dec. 31, 2018																																						10,711,000				10,711,063
Balance at Dec. 31, 2018																																						$ 11	728,804	(657,647)	$ (3,054)	$ 68,114
Net loss																																								(27,475)		(27,475)
Issuance of stock (in shares)		2,917,000																														32,000
Issuance of stock		$ 3	$ 27,723			$ 27,726
Vesting of restricted stock units (in shares)																																						37,000
Vesting of restricted stock units
Withholding tax payments related to net share settlements of restricted stock units (in shares)
Withholding tax payments related to net share settlements of restricted stock units																																							(151)			(151)
Withholding tax payments related to net share settlements of restricted stock units (in shares)
Stock-based compensation expense																																							6,721			$ 6,721
Balance (in shares) at Dec. 31, 2019																																						13,697,000				13,697,395
Balance at Dec. 31, 2019																																						$ 14	$ 763,097	$ (685,122)	$ (3,054)	$ 74,935

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (27,475,000)	$ (20,533,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Net loss on extinguishment of debt	1,794,000	3,345,000
Recognition of deferred revenue	(198,000)	(1,093,000)
Depreciation	195,000	160,000
Amortization of debt discount	163,000	863,000
Stock-based compensation	6,721,000	955,000
Non-cash lease expense	917,000
Net realized gain on sale of marketable securities	(75,000)	0
Gain on sale of equipment		(9,000)
Changes in:
Prepaid expenses and other current assets	688,000	302,000
Accounts payable	(2,468,000)	997,000
Collaboration and device development payable	(767,000)	(510,000)
Accrued expenses	(3,191,000)	(276,000)
Operating lease liabilities	(974,000)
Other liabilities	7,000	18,000
Net cash used in operating activities	(24,663,000)	(15,781,000)
Cash flows from investing activities:
Sale of marketable securities	13,988,000
Purchase of marketable securities		(13,959,000)
Cash acquired in CVie acquisition		223,000
Purchase of property and equipment	(191,000)
Proceeds from sale of property and equipment		9,000
Net cash used in investing activities	13,797,000	(13,727,000)
Cash flows from financing activities:
Proceeds from private placement issuance of securities, net of expenses	22,982,000	32,893,000
Proceeds from loan payable, net of expenses	1,000,000	6,160,000
Repayment of loan payable	(2,063,000)	(160,000)
Proceeds from convertible note payable		1,500,000
Repayment of convertible note payable		(1,500,000)
Payments for taxes related to net share settlements of restricted stock units	(151,000)	(155,000)
Net cash provided by financing activities	21,768,000	38,738,000
Effect of exchange rates on cash and cash equivalents	472,000	88,000
Net increase/(decrease) in cash and cash equivalents	11,374,000	9,318,000
Cash, cash equivalents and restricted cash - beginning of year	11,358,000	2,040,000
Cash, cash equivalents and restricted cash - end of year	22,732,000	11,358,000
Supplementary disclosure of non-cash activity:
Prepayment of insurance through third-party financing	$ 708,000

Note 1 - The Company and Descri

Note 1 - The Company and Description of Business	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 We are a clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Our development programs are primarily focused in the treatment of acute cardiovascular and pulmonary diseases. Our lead cardiovascular product candidate is istaroxime, a first 2 KL4 KL4 19 2a KL4

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Basis of Accounting [Text Block]	Note 2 The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries (or the Company). Intercompany balances and transactions have been eliminated in consolidation. All adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. When necessary, prior year’s consolidated financial statements have been reclassified to conform to the current year presentation. The consolidated financial statements reflect a 1 3 April 29, 2020.

Note 3 - Business Combination

Note 3 - Business Combination	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 3 On December 21, 2018 ( 5,418,686 $67.5 In connection with the CVie Acquisition, our board of directors declared a dividend to the holders of record of outstanding shares of common stock, and holders of certain warrants to purchase common stock, that were outstanding on December 20, 2018 0.6148 987,722 five one first 3 815, Derivatives and Hedging - Contracts in Entity’s own Equity $12.5 two first 3 two three Significant Input Assumptions of Warrant Valuation Historical volatility 116 % Expected term (in years) 2.5 Risk-free interest rate 2.62 % On the Acquisition Date, we entered into an indemnification letter agreement (the Indemnification Letter Agreement) with Lee’s Pharmaceutical Holdings Limited (Lee’s), pursuant to which Lee’s agreed to indemnify the holders of issued and outstanding shares of common stock on December 20, 2018 ( not 328,000 one December 31, 2019. The aggregate purchase price has been allocated based on the fair value of assets acquired and liabilities assumed as of the acquisition date. The excess of the $67.5 not (in thousands) Cash and cash equivalents $ 193 Restricted cash 31 Prepaid expenses and other current assets 387 Property and equipment, net 76 Intangible assets 77,090 Total identifiable assets acquired $ 77,777 Current liabilities $ (2,590 ) Loans payable, current (7,944 ) Deferred tax liabilities, noncurrent (15,418 ) Other liabilities, noncurrent (7 ) Net identifiable assets acquired 51,818 Goodwill 15,682 Net assets acquired $ 67,500 The acquired identifiable intangible assets consist of in-process research and development (“IPR&D”) of approximately $77.1 See, 5 From the Acquisition Date to December 31, 2018, $0.5 The following table presents unaudited consolidated pro forma results of operations based on our historical financial statements and adjusted for the acquisition of CVie as if it occurred on January 1, 2018. not Year Ended December 31, (in thousands, except per share data) 2018 Pro forma net loss attributable to common shareholders $ (38,082 ) Pro forma EPS - basic and diluted $ (3.60 ) For the year ended December 31, 2018,

Note 4 - Liquidity Risks and Ma

Note 4 - Liquidity Risks and Management's Plans	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Liquidity Disclosures [Text Block]	Note 4 We are subject to risks common to companies in the biotechnology industry, including but not may third We have incurred net losses since inception. Our net loss was $27.5 $20.5 December 31, 2019 2018 December 31, 2019, $685.1 In the future, we will need to raise additional capital to continue funding our operations. We plan to obtain funding through a combination of public or private equity offerings, or strategic transactions including collaborations, licensing arrangements or other strategic partnerships. There is inherent uncertainty associated with these fundraising activities and, other than the funding recently committed by Lee’s Pharmaceutical (HK) Ltd. (Lee’s (HK)) as discussed below, they are not We recently entered into a binding commitment with Lee’s (HK), pursuant to which Lee’s HK will provide financing for the development of AEROSURF beginning April 1, 2020 September 30, 2020. September 30, 2020 September 30, 2020, Management considers the successful implementation of these plans and efforts to manage uncommitted spending, including AEROSURF development, and to carry out necessary cost saving measures to be probable. Therefore, we expect our plans will enable our cash and cash equivalents as of the filing of our Annual Report on Form 10 twelve Our funding requirements, however, are based on estimates that are subject to risks and uncertainties and may no 19 may

Note 5 - Accounting Policies an

Note 5 - Accounting Policies and Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 5 Principles of Consolidation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments Limited and its wholly-owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.). Business Combinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may Goodwill and Intangible Assets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (IPR&D) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may December 31, 2019 2018: (in thousands) Carrying Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is not may When testing our goodwill and indefinite-lived intangible assets for impairment, we can elect to perform a qualitative assessment to determine if it is more likely than not not December 1, 2019, The Company consists of one no no may not December 1, 2019, no When performing the quantitative impairment assessment for our indefinite-lived IPR&D intangible assets, we estimate the fair values of the assets using the multi-period excess earnings method (“MPEEM”). MPEEM is a variation of the income approach which estimates the fair value of an intangible asset based on the present value of the incremental after-tax cash flows attributable to the intangible asset. Significant factors considered in the calculation of IPR&D intangible assets include the risks inherent in the development process, including the likelihood of achieving commercial success and the cost and related time to complete the remaining development. Future cash flows for each project were estimated based on forecasted revenue and costs, taking into account the expected product life cycles, market penetration, and growth rates. Other significant estimates and assumptions inherent in this approach include: 1 2 3 4 Based on our annual quantitative impairment assessment of our indefinite-lived IPR&D intangible assets on December 1, 2019, not Foreign Currency Transactions The functional currency for our foreign subsidiaries is US Dollars. We remeasure monetary assets and liabilities that are not $0.5 $0.1 December 31, 2019 2018. Use of Estimates The preparation of financial statements, in conformity with accounting principles generally accepted in the U.S., requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments, money market funds, and US Treasury notes with a maturity from date of purchase of 90 Marketable Securities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 320, Investments—Debt and Equity Securities December 31, 2019, $75,000 zero no December 31, 2018. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security. Fair Value of Financial Instruments Our financial instruments consist principally of cash and cash equivalents and restricted cash. The fair values of our cash equivalents are based on quoted market prices. The carrying amount of cash equivalents is equal to their respective fair values at December 31, 2019 2018, Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three ten Restricted Cash Restricted cash consists principally of a $140,000 May 26, 2004 $14,000 (see, - 18 Leases Effective January 1, 2019, 842, Leases 842 not 840, Leases At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease based on the unique facts and circumstances present in the arrangement. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Operating lease liabilities and their corresponding operating lease right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may not 842, For contracts entered into on or after the effective date of ASC 842, 1 2 3 We evaluate the classification of our leases as either finance leases or operating leases. A lease is classified as a finance lease if any one no not Lease cost for our operating leases is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not 12 Long-lived Assets Our long-lived assets, primarily consisting of intangible assets, are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not No December 31, 2019 2018 no not Collaborative Arrangements We account for collaborative arrangements in accordance with applicable accounting guidance provided in ASC Topic 808, Collaborative Arrangements See, 16 Restructured Debt Liability - Contingent Milestone Payment In conjunction with the November 2017 see, 13 $15.0 October 27, 2017 ( not Deferred Revenue Deferred revenue represents amounts received prior to satisfying the revenue recognition criteria ( see 12 not 12 Deferred revenue primarily consists of amounts related to an upfront license fee received in July 2017 (see, 16 Revenue Recognition Effective January 1, 2018, 606, Revenue from Contracts with Customers 606, In accordance with ASC Topic 606, 606, five (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five 606, We have concluded that our government grants are not 606 not 958 605, Not not In the absence of applicable guidance under US GAAP, effective January 1, 2018, We believe this policy is consistent with the overarching premise in ASC Topic 606, no 606. We believe the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC Topic 606. Research and Development We account for research and development expense by the following categories: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with ASC Topic 730, Research and Development Stock-based Compensation Stock-based compensation is accounted for under the fair value recognition provisions of ASC Topic 718, Stock Compensation ( 718 See, - 15 Warrant Accounting We account for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging - Contracts in Entity’s Own Equity 815 Income Taxes We account for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not Beneficial Conversion Feature A beneficial conversion feature arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor (or in the money) at inception due to the conversion option having an effective conversion price that is less than the fair value of the underlying stock at the commitment date. Preferred Stock The issuance of Series A Convertible Preferred Stock (Preferred Shares) in the first 2017 $3.6 one first 2017. An additional discount to the Preferred Shares of $4.5 December 31, 2018, $1.7 December 31, 2018, no Convertible Note The issuance on July 2, 2018 $1.5 $1.5 $0.4 $0.4 $1.5 (see 11 December 27, 2018, $1.5 $0.4 $15.33 $12.00, 125,000 Net Loss per Common Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the years ended December 31, 2019 2018, 6.5 4.8 December 31, 2019 2018, We do not Concentration of Suppliers We currently obtain the active pharmaceutical ingredients (APIs) of our KL4 third KL4 one Segment and Geographic Information We currently operate in one one not December 31, 2019 2018 $77.1 $15.7 December 31, 2019 2018. Recent Accounting Pronouncements Recently Adopted Accounting Standards In February 2016, 2016 02, Leases 2016 02 2016 02 842 840, Leases 842 2018. January 1, 2019 not not January 1, 2019. 840 842 not 12 not $2.2 $2.0 842 $72,000 $139,000 not 21 In January 2017, 2017 04, Intangibles-Goodwill and Other (Topic 350 second December 15, 2019 January 1, 2019 December 31, 2019. Recent Accounting Pronouncements In August 2018, 2018 13, Fair Value Measurement (Topic 820 2018 13 820. no 1 2 3 3 3 2018 13 December 15, 2019. 2018 13 In December 2019, 2019 12, Income Taxes (Topic 740 2019 12 740 December 15, 2020 not

Note 6 - License Revenue with A

Note 6 - License Revenue with Affiliate	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 6 Year Ended December 31, (in thousands) 2019 2018 License revenue with affiliate $ 198 $ 1,023 License revenue with affiliate for the years ended December 31, 2019 2018 606, January 1, 2018 (see, 5 16 no 606. second 2019 no

Note 7 - Fair Value Measurement

Note 7 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 7 Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three first two ● Level 1 ● Level 2 1 not ● Level 3 no Fair Value on a Recurring Basis Assets measured at fair value on a recurring basis are categorized in the table below as of December 31, 2019 2018: Fair Value Fair value measurement using December 31, (in thousands) 2019 Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 1,819 $ 1,819 $ - $ - U.S. Treasury notes 18,230 18,230 - - Total Assets $ 20,049 $ 20,049 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 103 $ 103 $ - $ - U.S. Treasury notes 6,018 6,018 Available-for-sale marketable securities: U.S. Treasury notes 13,959 13,959 - - Total Assets $ 20,080 $ 20,080 $ - $ -

Note 8 - Property and Equipment

Note 8 - Property and Equipment	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 8 Property and equipment is comprised of the following: December 31, (in thousands) 2019 2018 Manufacturing, laboratory & office equipment $ 4,313 $ 4,359 Furniture & fixtures 390 390 Leasehold improvements 2,469 2,469 Subtotal 7,172 7,218 Accumulated depreciation and amortization (6,374 ) (6,416 ) Property and equipment, net $ 798 $ 802 Depreciation expense on property and equipment was $0.2 December 31, 2019 2018.

Note 9 - Collaboration and Devi

Note 9 - Collaboration and Device Development Payable	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 9 Collaboration and device development payable represents amounts due to Battelle under a collaboration agreement related to the development of our phase 3 16 June 2012 2 December 31, 2019 2018, $2.0 $2.6 Restructuring of the Battelle Payables On December 7, 2018, 6.0% $3.0 30 December 2018 $1.0 see 14 $1.0 $1.25 five $0.25 $25.0 $35.0 two first one 3 December 31, 2019, January 7, 2020. December 31, 2019. March 30, 2020, no April 15, 2020 no September 1, 2020. Management determined the payment restructuring agreement of the Battelle Payables does not not not In connection with the payment restructuring agreement, we also issued to Battelle Series E Warrants (Series E Warrants) to purchase 25,000 $19.50 may 5 December 11, 2023. may not 9.99% The Series E Warrants are derivatives that qualify for an exemption from liability accounting as provided for in ASC Topic 815, five Significant Input Assumptions of Warrant Valuation Historical volatility 103 % Expected term (in years) 5 Risk-free interest rate 2.70 % As of December 31, 2019, $0.4 Extinguishment of Collaboration and Device Development Payable On December 21, 2018, $1.0 100,607 $9.9396 17,103 $11.04 33,201 $12.15 18 may 5 The conversion of the Battelle Payables is treated as an extinguishment of outstanding liabilities. We recorded a loss on extinguishment of debt of approximately $0.5 $1.5 December 21, 2018 $1.0

Note 10 - Accrued Expenses

Note 10 - Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	Note 10 Accrued expenses are comprised of the following: December 31, (in thousands) 2019 2018 Research and development $ 1,415 2,361 Professional fees 543 $ 2,473 Salaries, bonus & benefits 696 815 Manufacturing operations 183 212 Other 389 604 Total accrued expenses $ 3,226 $ 6,465

Note 11 - Loan Payable - Curren

Note 11 - Loan Payable - Current Portion and Non-current Portion	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Short-term Debt [Text Block]	Note 11 Loans Payable – Current Portion 2019 On October 24, 2019, $1.0 2019 2019 October 28, 2019, 6% December 2019 2019 December 2019 201 8 Loan s In January 2018 March 2018, $1.5 $1.0 2018 one 6% December 31, 2018. March 1, 2018, During the third fourth 2018, 2018 2018 August 14, 2018 $0.3 2018 August 29, 2018, $0.48 September 12, 2018 $0.5 September 27, 2018 $0.5 October 19, 2018 $0.43 November 2, 2018 $0.5 November 19, 2018 $0.35 December 5, 2018 $0.6 6% $30 March 31, 2019. December 5, 2018, On December 21, 2018, December 2018 see $6.0 $2.5 2018 $3.5 2018 December 2018 not December 2018 third $3.2 December 21, 2018 $160,000 $182,000 December 27, 2018. 2018 2018 Assumption of LPH II debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $3.5 From April 24, 2018 November 16, 2018, four $3.5 $0.5 April 2018, April 2018 $0.3 September 2018, September 2018 $0.15 October 2018, October 2018 $2.5 November 2018, November 2018 April 2018 September 2018 October 2018 September 2018 4% one During the quarter ended March 31, 2019, $0.45 April 2018 $50,000 April 2019. December 2019, December 2019 see $2.95 September 2018 October 2018 November 2018 December 2019 325,607 $9.06 162,804 $12.09 sixth 5 not December 2019 third $1.8 December 6, 2019 $127,000 December 2019 December 31, 2019 no Loan payable to Bank Direct Capital Finance In May 2019, $0.7 5.35% December 31, 2019, $0.2 first 2020. Loans Payable – Non-current Portion Assumption of bank debt as part of the CVie Acquisition As part of the CVie Acquisition, we assumed approximately $4.5 In September 2016, 12 $2.9 $5.8 September 2017. 110% not 90 0.91%. September 11, 2019 six March 11, 2020. March 2020, March 2022. $5.0 1.17% 24 six two As of December 31, 2019, $4.6 March 2022,

Note 12 - Convertible Note Paya

Note 12 - Convertible Note Payable	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Convertible Note Payable Disclosure [Text Block]	Note 12 On July 2, 2018, $1.5 two $1.0 $0.5 July 23, 2018. December 31, 2018 15% $4.00. In connection with the Note, we issued to Panacea warrants (the “Series D Warrants”) to purchase 62,500 $12.00 may six fifth may not 9.99% may sixty-one We recorded the Note as current debt at its face value of $1.5 $0.4 $0.4 $1.5 815, Derivatives and Hedging - Contracts in Entity’s Own Equity, The fair value at issuance of the Panacea Warrants was determined using the Black-Scholes option-pricing model. The input assumptions used in the valuation are the historical volatility of our common stock price, the expected term of the warrants, and the risk-free interest rate based on the five Significant Input Assumptions of Warrant Valuation Historical volatility 103 % Expected term (in years) 5 Risk-free interest rate 2.75 % Extinguishment of Panacea Convertible Promissory Note On December 27, 2018, $1.5 $0.4 $15.33 $12.00, 125,000

Note 13 - Restructured Debt Lia

Note 13 - Restructured Debt Liability	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Long-term Debt [Text Block]	Note 13 December 31, December 31, (in thousands) 2019 2018 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000 On November 1, 2017, $25 8,333 $2,360.40 $2.5 23,703 2% $15.0 $15.0 see 5 not

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 14 Private Placement Offerings December 2019 On December 6, 2019 December 2019 2,916,666 $9.06, $26.4 $2.95 1,458,333 $12.09 six five may no may not 4.99% not 19.99% 1, January 21, 2020, 2,916,666 1,458,333 December 2018 On December 21, 2018, 3,928,513 $9.9396, $39.0 2018 $6.0 $1.0 667,847 $11.04 18 1,296,410 $12.15 5 December 2018 December 2018 may not 9.99% December 2018 April 2018 In April 2018, $2.6 $14.40. 180,555 45,139 $16.56 6 seventh Common Shares Reserved for Future Issuance Common shares reserved for potential future issuance upon exercise of warrants The chart below summarizes shares of our common stock reserved for future issuance upon the exercise of warrants: December 31, Expiration (in thousands, except price per share data) 2019 2018 Exercise Price Date Investors - December 2019 financing 1,458 - $ 12.09 12/06/24 Investors - AEROSURF 988 988 $ - 02/14/24 Investors - December 2018 financing - long-term 1,296 1,296 $ 12.15 12/04/23 Investors - December 2018 financing - short-term 668 668 $ 11.04 06/24/20 Battelle - 2018 payables restructuring agreement (1) 25 25 $ 19.50 12/07/23 Panacea Venture Management Company Ltd. 63 63 $ 12.00 07/02/23 LPH II Investments Limited 45 45 $ 16.56 04/04/25 Investors - February 2017 financing 117 117 $ 82.20 02/15/24 Investors - July 2015 financing 80 80 $ 588.00 07/22/22 Battelle - 2014 collaboration agreement 1 1 $ 4,200.00 10/10/24 Total 4,741 3,283 ( 1 See, - 16 Common shares reserved for potential future issuance upon exercise of stock options or granting of additional equity incentive awards On December 24, 2018, 1.4 As of December 31, 2019 2018, 0.1 0.5 2011

Note 15 - Stock Options and Sto

Note 15 - Stock Options and Stock-based Employee Compensation	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 15 Long-Term Incentive Plans We have the 2011 2007 There are 2.0 2011 0.1 may An administrative committee (the Committee - currently the Compensation Committee of the Board of Directors) or Committee delegates may may Stock options and restricted stock units (RSUs) outstanding and available for future issuance are as follows: December 31, (in thousands) 2019 2018 Stock Options and RSUs Outstanding 2011 Plan 1,804 1,519 Non-Plan 3 3 Total Outstanding 1,807 1,522 Available for Future Grants under 2011 Plan 149 484 No 2011 may three first 10 February 1, 2016. 5635 4 three first 10 A summary of activity under our long-term incentive plans is presented below: (in thousands, except for weighted-average data) Stock Options Shares Weighted- Weighted- Outstanding at January 1, 2019 1,472 $ 20.19 Granted 382 9.99 Forfeited or expired (82 ) 40.74 Outstanding at December 31, 2019 1,772 $ 17.61 9.0 Vested and exercisable at December 31, 2019 521 $ 29.34 8.9 Vested and expected to vest at December 31, 2019 1,692 $ 17.55 9.0 (in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2019 50 $ 12.87 Awarded 83 11.85 Cancelled (48 ) 12.99 Vested (50 ) 12.87 Unvested at December 31, 2019 35 $ 11.85 Based upon application of the Black-Scholes option-pricing formula described below, the weighted-average grant-date fair value of options granted during the years ended December 31, 2019 2018 $10.02 $10.17, December 31, 2019 2018 $11.85 $12.66, December 31, 2019 $0. Stock-Based Compensation We recognized stock-based compensation expense in accordance with ASC Topic 718 $6.7 $1.0 December 31, 2019 2018. Stock-based compensation expense was classified as follows: Year Ended (in thousands) 2019 2018 Research and development $ 1,932 $ 232 Selling, general and administrative 4,789 723 Total $ 6,721 $ 955 The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities are based upon the historical volatility of our common stock and other factors. We also use historical data and other factors to estimate option exercises, employee terminations and forfeiture rates. The risk-free interest rates are based upon the US Treasury yield curve in effect at the time of the grant. Year Ended 2019 2018 Weighted average expected volatility 95 % 93 % Weighted average expected term (years) 6.6 7.0 Weighted average risk-free interest rate 2.6 % 2.7 % Expected dividends - - The total fair value of the underlying shares of the options vested during 2019 2018 $5.6 $0.6 December 31, 2019, $10.7 2011 1.9

Note 16 - Collaboration, Licens

Note 16 - Collaboration, Licensing and Research Funding Agreements	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Corporate Partnership, Licensing and Research Funding Agreements [Text Block]	Note 16 Collaboration Agreement Battelle Memorial Institute In October 2014, 3 2 2b three 3 3 3 first two $25 $35 In December 2018, March 2020. See, 9 Licensing and Research Funding Agreements Lee’s Pharmaceutical (HK) Ltd. In June 2017, KL4 2012 12 August 2017 Under the License Agreement, Lee’s made an upfront payment to us of $1 may $37.5 may 3 In August 2017, $3.9 October 31, 2017, $10 November 1, 2017. $35.8 We will be eligible to receive tiered royalties based on a percent of Net Sales, depending on the product, in the range of high single to low-to-mid double-digit percentages. Royalties are payable on a country-by-country basis until the latest of (A) the expiration of the last valid patent claim covering the product in the country of sale, (B) the expiration or revocation of any applicable regulatory exclusivity in the country of sale, and (C) ten 10 first three one Under the License Agreement, Lee’s will be responsible for all activities related to development, regulatory approval and commercialization of KL4 ten 10 first first first first not Accounting Analysis under ASC 606 In evaluating the License Agreement in accordance with ASC Topic 606, KL4 606 10 25 16A, We concluded that the licensing rights were not not not not With respect to Amendment No. 1, 2014 09, $1.0 $0.3 No. 1. $1.3 KL4 November 2017 second 2019 no Regulatory and commercialization milestones were excluded from the transaction price, as all milestone amounts were fully constrained under the guidance. As part of our evaluation of the constraint, we considered a number of factors in determining whether there is significant uncertainty associated with the future events that would result in the milestone payments. Those factors include: our financial position; ongoing delays in our development activities and with initiating our phase 3 2b 2015 not (see, 1A Consideration related to sales-based milestones and royalties will be recognized when the related sales occur, provided that the reported sales are reliably measurable and that we have no Philip Morris USA Inc. and Philip Morris Products S.A. Under license agreements with Philip Morris USA Inc. (PMUSA) and Philip Morris Products S.A. (PMPSA), we hold exclusive worldwide licenses to the ADS technology for use with pulmonary surfactants (alone or in combination with any other pharmaceutical compound(s)) for all respiratory diseases and conditions (the foregoing uses in each territory, the Exclusive Field), and an exclusive license in the US for use with certain non-surfactant drugs to treat a wide range of pediatric and adult respiratory indications in hospitals and other health care institutions. We generally are obligated to pay royalties at a rate equal to a low single-digit percent of sales of products sold in the Exclusive Field (as defined in the license agreements) in the territories, including sales of aerosol devices that are not 2014 2018 2019, $400,000 Johnson & Johnson and Ortho Pharmaceutical Corporation We, Johnson & Johnson (J&J) and its wholly-owned subsidiary, Ortho Pharmaceutical Corporation, are parties to a license agreement granting to us an exclusive worldwide license to the J&J proprietary KL4 $2.5 $1.0 $0.5 2012 Laboratorios del Dr. Esteve, S.A. We have a strategic alliance with Laboratorios del Dr. Esteve, S.A. (Esteve) for the development, marketing and sales of a broad portfolio of potential KL4 May 2002 January 2013. KL4 3 2004 10% $20 KL4 Universita degli Studi di Milano-Bicocca Effective April 13, 2015, Ca2 2a SERCA2a SERCA2a three no Under the collaboration agreement, intellectual property resulting from the collaboration, including patents and know-how, will be jointly owned by the parties. For the development of any new SERCA2a 12 not 0.1 $0.1 SERCA2a 1.5 $1.7 ten first Also, under the collaboration agreement, we have provided funds aggregating € 0.2 $0.2 2019.

Note 17 - Related Party Transac

Note 17 - Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 17 Lee’s Pharmaceutical Holdings Limited As of December 31, 2019 2018, 35% 40%, We entered into the following transactions with Lee’s during 2018 2019: ● During 2018, see 11 ● In April 2018, $2.6 see 14 ● In conjunction with the CVie Acquisition in December 2018, 49% see 3 ● In December 2018, $6.0 see 11 ● In October 2019, see 11 ● In December 2019, see 14 ● In December 2019, $2.95 see 11 ● Our $4.6 see 11 ● As of December 31, 2018 2019, $0.5 December 31, 2019 $0.8 KL4 Panacea Venture and KPCB-China Mr. James Huang, who in connection with the CVie Acquisition in December 2018 2011, 2018 2019 ● In July 2018, $1.5 December 2018 ( see 12 ● In December 2018, 38,138 ● In December 2018, 27% see 3 ● In December 2018 December 2019, see 14 ● In December 2019, 32,143 As of December 31, 2019, 15% 11%, December 31, 2018, 14%

Note 18 - Commitments

Note 18 - Commitments	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments Disclosure [Text Block]	Note 18 We have no 21,

Note 19 - Litigation

Note 19 - Litigation	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	Note 19 We are not We have from time to time been involved in disputes and proceedings arising in the ordinary course of business, including in connection with the conduct of our clinical trials. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not no not

Note 20 - Income Taxes

Note 20 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 20 Since our inception, we have never recorded a provision or benefit for federal and state income taxes. The reconciliation of the income tax benefit computed at the federal statutory rates to our recorded tax benefit for the years ended December 31, 2019 2018 December 31, (in thousands) 2019 2018 Income tax benefit, statutory rates $ (5,770 ) $ (4,312 ) State taxes on income, net of federal benefit (1,182 ) (535 ) Impact of tax reform - 5 Research and development tax credit (934 ) (351 ) Foreign rate differential 22 24 Employee related and other 1,983 2,875 Interest related 79 186 Income tax expense / (benefit), statutory rates (5,802 ) (2,108 ) Valuation allowance 5,802 2,108 Income tax benefit, net $ - $ - The tax effects of temporary differences that give rise to deferred tax assets and deferred tax liabilities, at December 31, 2019 2018, December 31, (in thousands) 2019 2018 Long-term deferred assets: Net operating loss carryforwards (federal and state) $ 180,979 $ 176,759 Research and development tax credit 17,599 16,718 Compensation expense on stock 2,142 1,121 Charitable contribution carryforward - - Other accrued 934 1,016 Deferred revenue - 57 Depreciation 128 309 Total long-term deferred tax assets 201,782 195,980 Long-term deferred liabilities: IPRD (15,419 ) (15,476 ) Total long-term deferred tax liabilities (15,419 ) (15,476 ) Valuation allowance (201,782 ) (195,980 ) Deferred tax liabilities, net $ (15,419 ) $ (15,476 ) We are in a net deferred tax liability position at December 31, 2019 2018. not December 31, 2019 2018, 2019 2018. At December 31, 2019 2018, $618.9 $606.6 $16.9 $16.7 $0.1 $618.9 $35.9 2038. At December 31, 2019 2018, $597.1 $584.8 $597.1 $582.7 6 Utilization of net operating loss (NOL) and research and development (R&D) credit carryforwards may 382 1986 may may A full valuation allowance has been provided against our deferred tax assets and, if a future assessment requires an adjustment, an adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no

Note 21 - Leases

Note 21 - Leases	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 21 Our operating leases consist primarily of facility leases for our operations in Warrington, Pennsylvania and Taipei, Taiwan. We maintain our corporate headquarters and operations in Warrington, Pennsylvania. The facility serves as the main operating facility for drug and device development, regulatory, analytical technical services, research and development, and administration. We also maintain offices in Taipei, Taiwan, the former headquarters of CVie Therapeutics, where we perform certain manufacturing development and preclinical activities related to our cardiovascular drug product candidates. In February 2018, 30,506 21,189 $225,000 $140,000. April 2019, 2,635 1,317 December 31, 2019 $1.5 Throughout the term of our leases, we are responsible for paying certain variable lease costs, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. The following table contains a summary of the lease costs recognized under ASC 842 twelve December 31, 2019: Twelve Months Ended (in thousands) 2019 Operating lease cost $ 889 Variable lease cost 22 Total lease cost $ 911 Other Information Operating cash flows used for operating leases $ 951 Operating lease liabilities arising from obtaining right-of-use assets $ 364 Weighted average remaining lease term (in years) 2.2 Weighted average incremental borrowing rate 9.00 % Rent expense under ASC 840 $0.8 December 31, 2018. Future minimum lease payments under our non-cancelable operating leases as of December 31, 2019, As of (in thousands) 2019 2020 850 2021 640 2022 180 2023 23 Thereafter - Total lease payments 1,693 Less imputed interest (149 ) Total operating lease liabilities at December 31, 2019 1,544

Note 22 - Selected Quarterly Fi

Note 22 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Quarterly Financial Information [Text Block]	Note 22 The following tables contain unaudited statement of operations information for each quarter of 2019 2018. not 2019 Quarters Ended: (in thousands, except per share data) Mar. 31 June 30 Sept. 30 Dec. 31 Total Year Revenues: Grant revenue $ - $ - $ - $ - $ - License revenue with affiliate 40 158 - - 198 Total revenues 40 158 - - 198 Expenses: Research and development 3,342 3,413 3,792 2,140 12,687 Selling, general and administrative 3,355 3,240 3,395 2,414 12,404 Total expenses 6,697 6,653 7,187 4,554 25,091 Operating loss (6,657 ) (6,495 ) (7,187 ) (4,554 ) (24,893 ) Other income / (expense), net 120 58 61 (2,821 ) (2,582 ) Net (loss) / income $ (6,537 ) $ (6,437 ) $ (7,126 ) $ (7,375 ) $ (27,475 ) Net (loss) / income per common share - basic and diluted $ (0.61 ) $ (0.60 ) $ (0.66 ) $ (0.64 ) $ (2.51 ) Weighted average number of common shares outstanding - basic and diluted 10,714 10,730 10,730 11,532 10,928 2018 Quarters Ended: (in thousands, except per share data) Mar. 31 June 30 Sept. 30 Dec. 31 Total Year Revenues: Grant revenue $ - $ 695 $ 70 $ - $ 765 License revenue with affiliate 204 356 159 304 1,023 Total revenues 204 1,051 229 304 1,788 Expenses: Research and development 3,118 2,879 2,197 2,368 10,562 Selling, general and administrative 1,926 1,208 1,500 2,787 7,421 Total expenses 5,044 4,087 3,697 5,155 17,983 Operating loss (4,840 ) (3,036 ) (3,468 ) (4,851 ) (16,195 ) Other income / (expense), net 328 (16 ) (459 ) (4,191 ) (4,338 ) Net (loss) / income $ (4,512 ) $ (3,052 ) $ (3,927 ) $ (9,042 ) $ (20,533 ) AEROSURF warrant dividend - - - (12,505 ) (12,505 ) Deemed dividend on preferred stock - - - (1,718 ) (1,718 ) Net (loss) / income attributable to common shareholders $ (4,512 ) $ (3,052 ) $ (3,927 ) $ (23,265 ) $ (34,756 ) Net (loss) / income per common share - basic and diluted $ (4.19 ) $ (2.44 ) $ (3.13 ) $ (9.71 ) $ (23.20 ) Weighted average number of common shares outstanding - basic and diluted 1,076 1,250 1,256 2,397 1,498

Note 23 - Subsequent Events

Note 23 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 23 AEROSURF Funding Term Sheet On March 18, 2020, The Term Sheet provides that in connection with the development of AEROSURF, Lee’s will make non-refundable payments to us in the amount of (i) $1.0 no April 1, 2020; ( $1.4 no July 1, 2020; $1.5 no September 1, 2020; $0.4 August 31, 2020, ( $4.5 September 1, 2020. September 30, 2020. The Term Sheet provides that, until such time as we have repaid 125% 50% KL4/AEROSURF June 12, 2017 ( third not The Term Sheet also provides that Lee’s and we will amend existing provisions of the License Agreement to reduce future royalty payments payable to us from Lee’s on net sales of certain licensed products, reducing the range of such royalty payment percentage from a range of high single to low mid-double digits to a range of mid-single to low-double digits. O-Bank Facility In March 2020, March 2022. $5.0 1.17% 24 six two As of December 31, 2019, $4.6 March 2022, Coronavirus Outbreak In December 2019, 19, March 2020, 19 19 April 1, 2020, not 19 19 2020, may may

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments Limited and its wholly-owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).
Business Combinations Policy [Policy Text Block]	Business Combinations We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Intangible Assets We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (IPR&D) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not may December 31, 2019 2018: (in thousands) Carrying Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090 Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is not may When testing our goodwill and indefinite-lived intangible assets for impairment, we can elect to perform a qualitative assessment to determine if it is more likely than not not December 1, 2019, The Company consists of one no no may not December 1, 2019, no When performing the quantitative impairment assessment for our indefinite-lived IPR&D intangible assets, we estimate the fair values of the assets using the multi-period excess earnings method (“MPEEM”). MPEEM is a variation of the income approach which estimates the fair value of an intangible asset based on the present value of the incremental after-tax cash flows attributable to the intangible asset. Significant factors considered in the calculation of IPR&D intangible assets include the risks inherent in the development process, including the likelihood of achieving commercial success and the cost and related time to complete the remaining development. Future cash flows for each project were estimated based on forecasted revenue and costs, taking into account the expected product life cycles, market penetration, and growth rates. Other significant estimates and assumptions inherent in this approach include: 1 2 3 4 Based on our annual quantitative impairment assessment of our indefinite-lived IPR&D intangible assets on December 1, 2019, not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Transactions The functional currency for our foreign subsidiaries is US Dollars. We remeasure monetary assets and liabilities that are not $0.5 $0.1 December 31, 2019 2018.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements, in conformity with accounting principles generally accepted in the U.S., requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments, money market funds, and US Treasury notes with a maturity from date of purchase of 90
Marketable Securities, Policy [Policy Text Block]	Marketable Securities Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 320, Investments—Debt and Equity Securities December 31, 2019, $75,000 zero no December 31, 2018. We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Our financial instruments consist principally of cash and cash equivalents and restricted cash. The fair values of our cash equivalents are based on quoted market prices. The carrying amount of cash equivalents is equal to their respective fair values at December 31, 2019 2018,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three ten
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash Restricted cash consists principally of a $140,000 May 26, 2004 $14,000 (see, - 18
Lessee, Leases [Policy Text Block]	Leases Effective January 1, 2019, 842, Leases 842 not 840, Leases At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease based on the unique facts and circumstances present in the arrangement. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Operating lease liabilities and their corresponding operating lease right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may not 842, For contracts entered into on or after the effective date of ASC 842, 1 2 3 We evaluate the classification of our leases as either finance leases or operating leases. A lease is classified as a finance lease if any one no not Lease cost for our operating leases is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not 12
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-lived Assets Our long-lived assets, primarily consisting of intangible assets, are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not No December 31, 2019 2018 no not
Collaborative Arrangement, Accounting Policy [Policy Text Block]	Collaborative Arrangements We account for collaborative arrangements in accordance with applicable accounting guidance provided in ASC Topic 808, Collaborative Arrangements See, 16
Restructured Debt Liability, Contingent Milestone Payment, Policy [Policy Text Block]	Restructured Debt Liability - Contingent Milestone Payment In conjunction with the November 2017 see, 13 $15.0 October 27, 2017 ( not
Revenue [Policy Text Block]	Deferred Revenue Deferred revenue represents amounts received prior to satisfying the revenue recognition criteria ( see 12 not 12 Deferred revenue primarily consists of amounts related to an upfront license fee received in July 2017 (see, 16
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Effective January 1, 2018, 606, Revenue from Contracts with Customers 606, In accordance with ASC Topic 606, 606, five (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five 606, We have concluded that our government grants are not 606 not 958 605, Not not In the absence of applicable guidance under US GAAP, effective January 1, 2018, We believe this policy is consistent with the overarching premise in ASC Topic 606, no 606. We believe the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC Topic 606.
Research and Development Expense, Policy [Policy Text Block]	Research and Development We account for research and development expense by the following categories: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with ASC Topic 730, Research and Development
Share-based Payment Arrangement [Policy Text Block]	Stock-based Compensation Stock-based compensation is accounted for under the fair value recognition provisions of ASC Topic 718, Stock Compensation ( 718 See, - 15
Derivatives, Policy [Policy Text Block]	Warrant Accounting We account for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging - Contracts in Entity’s Own Equity 815
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not
Stockholders' Equity Note, Convertible Preferred Stock, Beneficial Conversion Feature, Policy [Policy Text Block]	Beneficial Conversion Feature A beneficial conversion feature arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor (or in the money) at inception due to the conversion option having an effective conversion price that is less than the fair value of the underlying stock at the commitment date. Preferred Stock The issuance of Series A Convertible Preferred Stock (Preferred Shares) in the first 2017 $3.6 one first 2017. An additional discount to the Preferred Shares of $4.5 December 31, 2018, $1.7 December 31, 2018, no Convertible Note The issuance on July 2, 2018 $1.5 $1.5 $0.4 $0.4 $1.5 (see 11 December 27, 2018, $1.5 $0.4 $15.33 $12.00, 125,000
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the years ended December 31, 2019 2018, 6.5 4.8 December 31, 2019 2018, We do not
Concentration of Suppliers [Policy Text Block]	Concentration of Suppliers We currently obtain the active pharmaceutical ingredients (APIs) of our KL4 third KL4 one
Segment Reporting, Policy [Policy Text Block]	Segment and Geographic Information We currently operate in one one not December 31, 2019 2018 $77.1 $15.7 December 31, 2019 2018.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Recently Adopted Accounting Standards In February 2016, 2016 02, Leases 2016 02 2016 02 842 840, Leases 842 2018. January 1, 2019 not not January 1, 2019. 840 842 not 12 not $2.2 $2.0 842 $72,000 $139,000 not 21 In January 2017, 2017 04, Intangibles-Goodwill and Other (Topic 350 second December 15, 2019 January 1, 2019 December 31, 2019. Recent Accounting Pronouncements In August 2018, 2018 13, Fair Value Measurement (Topic 820 2018 13 820. no 1 2 3 3 3 2018 13 December 15, 2019. 2018 13 In December 2019, 2019 12, Income Taxes (Topic 740 2019 12 740 December 15, 2020 not

Note 3 - Business Combination (

Note 3 - Business Combination (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	(in thousands) Cash and cash equivalents $ 193 Restricted cash 31 Prepaid expenses and other current assets 387 Property and equipment, net 76 Intangible assets 77,090 Total identifiable assets acquired $ 77,777 Current liabilities $ (2,590 ) Loans payable, current (7,944 ) Deferred tax liabilities, noncurrent (15,418 ) Other liabilities, noncurrent (7 ) Net identifiable assets acquired 51,818 Goodwill 15,682 Net assets acquired $ 67,500
Business Acquisition, Pro Forma Information [Table Text Block]	Year Ended December 31, (in thousands, except per share data) 2018 Pro forma net loss attributable to common shareholders $ (38,082 ) Pro forma EPS - basic and diluted $ (3.60 )
Warrants Issued for CVie Acquisition [Member]
Notes Tables
Schedule of Assumptions Used for Warrant Valution [Table Text Block]	Significant Input Assumptions of Warrant Valuation Historical volatility 116 % Expected term (in years) 2.5 Risk-free interest rate 2.62 %

Note 5 - Accounting Policies _2

Note 5 - Accounting Policies and Recent Accounting Pronouncements (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	(in thousands) Carrying Value Istaroxime drug candidate $ 22,340 Rostafuroxin drug candidate 54,750 Total $ 77,090

Note 6 - License Revenue with_2

Note 6 - License Revenue with Affiliate (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, (in thousands) 2019 2018 License revenue with affiliate $ 198 $ 1,023

Note 7 - Fair Value Measureme_2

Note 7 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Fair value measurement using December 31, (in thousands) 2019 Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 1,819 $ 1,819 $ - $ - U.S. Treasury notes 18,230 18,230 - - Total Assets $ 20,049 $ 20,049 $ - $ - Fair Value Fair value measurement using December 31, (in thousands) 2018 Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 103 $ 103 $ - $ - U.S. Treasury notes 6,018 6,018 Available-for-sale marketable securities: U.S. Treasury notes 13,959 13,959 - - Total Assets $ 20,080 $ 20,080 $ - $ -

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, (in thousands) 2019 2018 Manufacturing, laboratory & office equipment $ 4,313 $ 4,359 Furniture & fixtures 390 390 Leasehold improvements 2,469 2,469 Subtotal 7,172 7,218 Accumulated depreciation and amortization (6,374 ) (6,416 ) Property and equipment, net $ 798 $ 802

Note 9 - Collaboration and De_2

Note 9 - Collaboration and Device Development Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Series E Warrants [Member]
Notes Tables
Schedule of Assumptions Used for Warrant Valution [Table Text Block]	Significant Input Assumptions of Warrant Valuation Historical volatility 103 % Expected term (in years) 5 Risk-free interest rate 2.70 %

Note 10 - Accrued Expenses (Tab

Note 10 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, (in thousands) 2019 2018 Research and development $ 1,415 2,361 Professional fees 543 $ 2,473 Salaries, bonus & benefits 696 815 Manufacturing operations 183 212 Other 389 604 Total accrued expenses $ 3,226 $ 6,465

Note 12 - Convertible Note Pa_2

Note 12 - Convertible Note Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Series D Warrants [Member]
Notes Tables
Schedule of Assumptions Used for Warrant Valution [Table Text Block]	Significant Input Assumptions of Warrant Valuation Historical volatility 103 % Expected term (in years) 5 Risk-free interest rate 2.75 %

Note 13 - Restructured Debt L_2

Note 13 - Restructured Debt Liability (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	December 31, December 31, (in thousands) 2019 2018 Restructured debt liability - contingent milestone payments $ 15,000 $ 15,000

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Common Shares Reserved for Future Issuance, Warrants [Table Text Block]	December 31, Expiration (in thousands, except price per share data) 2019 2018 Exercise Price Date Investors - December 2019 financing 1,458 - $ 12.09 12/06/24 Investors - AEROSURF 988 988 $ - 02/14/24 Investors - December 2018 financing - long-term 1,296 1,296 $ 12.15 12/04/23 Investors - December 2018 financing - short-term 668 668 $ 11.04 06/24/20 Battelle - 2018 payables restructuring agreement (1) 25 25 $ 19.50 12/07/23 Panacea Venture Management Company Ltd. 63 63 $ 12.00 07/02/23 LPH II Investments Limited 45 45 $ 16.56 04/04/25 Investors - February 2017 financing 117 117 $ 82.20 02/15/24 Investors - July 2015 financing 80 80 $ 588.00 07/22/22 Battelle - 2014 collaboration agreement 1 1 $ 4,200.00 10/10/24 Total 4,741 3,283

Note 15 - Stock Options and S_2

Note 15 - Stock Options and Stock-based Employee Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Share Based Compensation Arrangement by Stock Options and Restricted Stock Units Outstanding and Available for Future Issuance [Table Text Block]	December 31, (in thousands) 2019 2018 Stock Options and RSUs Outstanding 2011 Plan 1,804 1,519 Non-Plan 3 3 Total Outstanding 1,807 1,522 Available for Future Grants under 2011 Plan 149 484
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	(in thousands, except for weighted-average data) Stock Options Shares Weighted- Weighted- Outstanding at January 1, 2019 1,472 $ 20.19 Granted 382 9.99 Forfeited or expired (82 ) 40.74 Outstanding at December 31, 2019 1,772 $ 17.61 9.0 Vested and exercisable at December 31, 2019 521 $ 29.34 8.9 Vested and expected to vest at December 31, 2019 1,692 $ 17.55 9.0
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	(in thousands, except for weighted-average data) Restricted Stock Units Shares Weighted- Unvested at January 1, 2019 50 $ 12.87 Awarded 83 11.85 Cancelled (48 ) 12.99 Vested (50 ) 12.87 Unvested at December 31, 2019 35 $ 11.85
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended (in thousands) 2019 2018 Research and development $ 1,932 $ 232 Selling, general and administrative 4,789 723 Total $ 6,721 $ 955
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended 2019 2018 Weighted average expected volatility 95 % 93 % Weighted average expected term (years) 6.6 7.0 Weighted average risk-free interest rate 2.6 % 2.7 % Expected dividends - -

Note 20 - Income Taxes (Tables)

Note 20 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	December 31, (in thousands) 2019 2018 Income tax benefit, statutory rates $ (5,770 ) $ (4,312 ) State taxes on income, net of federal benefit (1,182 ) (535 ) Impact of tax reform - 5 Research and development tax credit (934 ) (351 ) Foreign rate differential 22 24 Employee related and other 1,983 2,875 Interest related 79 186 Income tax expense / (benefit), statutory rates (5,802 ) (2,108 ) Valuation allowance 5,802 2,108 Income tax benefit, net $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, (in thousands) 2019 2018 Long-term deferred assets: Net operating loss carryforwards (federal and state) $ 180,979 $ 176,759 Research and development tax credit 17,599 16,718 Compensation expense on stock 2,142 1,121 Charitable contribution carryforward - - Other accrued 934 1,016 Deferred revenue - 57 Depreciation 128 309 Total long-term deferred tax assets 201,782 195,980 Long-term deferred liabilities: IPRD (15,419 ) (15,476 ) Total long-term deferred tax liabilities (15,419 ) (15,476 ) Valuation allowance (201,782 ) (195,980 ) Deferred tax liabilities, net $ (15,419 ) $ (15,476 )

Note 21 - Leases (Tables)

Note 21 - Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	Twelve Months Ended (in thousands) 2019 Operating lease cost $ 889 Variable lease cost 22 Total lease cost $ 911 Other Information Operating cash flows used for operating leases $ 951 Operating lease liabilities arising from obtaining right-of-use assets $ 364 Weighted average remaining lease term (in years) 2.2 Weighted average incremental borrowing rate 9.00 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	As of (in thousands) 2019 2020 850 2021 640 2022 180 2023 23 Thereafter - Total lease payments 1,693 Less imputed interest (149 ) Total operating lease liabilities at December 31, 2019 1,544

Note 22 - Selected Quarterly _2

Note 22 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Quarterly Financial Information [Table Text Block]	2019 Quarters Ended: (in thousands, except per share data) Mar. 31 June 30 Sept. 30 Dec. 31 Total Year Revenues: Grant revenue $ - $ - $ - $ - $ - License revenue with affiliate 40 158 - - 198 Total revenues 40 158 - - 198 Expenses: Research and development 3,342 3,413 3,792 2,140 12,687 Selling, general and administrative 3,355 3,240 3,395 2,414 12,404 Total expenses 6,697 6,653 7,187 4,554 25,091 Operating loss (6,657 ) (6,495 ) (7,187 ) (4,554 ) (24,893 ) Other income / (expense), net 120 58 61 (2,821 ) (2,582 ) Net (loss) / income $ (6,537 ) $ (6,437 ) $ (7,126 ) $ (7,375 ) $ (27,475 ) Net (loss) / income per common share - basic and diluted $ (0.61 ) $ (0.60 ) $ (0.66 ) $ (0.64 ) $ (2.51 ) Weighted average number of common shares outstanding - basic and diluted 10,714 10,730 10,730 11,532 10,928 2018 Quarters Ended: (in thousands, except per share data) Mar. 31 June 30 Sept. 30 Dec. 31 Total Year Revenues: Grant revenue $ - $ 695 $ 70 $ - $ 765 License revenue with affiliate 204 356 159 304 1,023 Total revenues 204 1,051 229 304 1,788 Expenses: Research and development 3,118 2,879 2,197 2,368 10,562 Selling, general and administrative 1,926 1,208 1,500 2,787 7,421 Total expenses 5,044 4,087 3,697 5,155 17,983 Operating loss (4,840 ) (3,036 ) (3,468 ) (4,851 ) (16,195 ) Other income / (expense), net 328 (16 ) (459 ) (4,191 ) (4,338 ) Net (loss) / income $ (4,512 ) $ (3,052 ) $ (3,927 ) $ (9,042 ) $ (20,533 ) AEROSURF warrant dividend - - - (12,505 ) (12,505 ) Deemed dividend on preferred stock - - - (1,718 ) (1,718 ) Net (loss) / income attributable to common shareholders $ (4,512 ) $ (3,052 ) $ (3,927 ) $ (23,265 ) $ (34,756 ) Net (loss) / income per common share - basic and diluted $ (4.19 ) $ (2.44 ) $ (3.13 ) $ (9.71 ) $ (23.20 ) Weighted average number of common shares outstanding - basic and diluted 1,076 1,250 1,256 2,397 1,498

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Apr. 29, 2020
Forecast [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	3

Note 3 - Business Combination_2

Note 3 - Business Combination (Details Textual) - CVie Investments [Member] $ in Millions	Dec. 31, 2018USD ($)	Dec. 21, 2018USD ($)shares
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares		5,418,686
Business Combination, Consideration Transferred, Total | $		$ 67.5
Indemnification Agreement, Shares Placed in Escrow (in shares) | shares		328,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $	$ 0.5
In Process Research and Development [Member]
Indefinite-lived Intangible Assets Acquired | $		$ 77.1
Warrants Issued for CVie Acquisition [Member]
Business Combination, Ratio of Warrants Received for Each Share of Common Stock and Certain Warrants		0.6148
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares		987,722
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares		1
Warrants and Rights Outstanding | $		$ 12.5

Note 3 - Business Combination -

Note 3 - Business Combination - Warrant Valuation Assumptions (Details) - Warrants Issued for CVie Acquisition [Member]	Dec. 21, 2018
Measurement Input, Price Volatility [Member]
Measurement input	1.16
Measurement Input, Expected Term [Member]
Measurement input	2.5
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.0262

Note 3 - Business Combination_3

Note 3 - Business Combination - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 21, 2018
Goodwill	$ 15,682	$ 15,682
CVie Investments [Member]
Cash and cash equivalents			$ 193
Restricted cash			31
Prepaid expenses and other current assets			387
Property and equipment, net			76
Intangible assets			77,090
Total identifiable assets acquired			77,777
Current liabilities			(2,590)
Loans payable, current			(7,944)
Deferred tax liabilities, noncurrent			(15,418)
Other liabilities, noncurrent			(7)
Net identifiable assets acquired			51,818
Goodwill			15,682
Net assets acquired			$ 67,500

Note 3 - Business Combination_4

Note 3 - Business Combination - Pro Forma Information (Details) - CVie Investments [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)$ / shares
Pro forma net loss attributable to common shareholders | $	$ (38,082)
Pro forma EPS - basic and diluted (in dollars per share) | $ / shares	$ (3.60)

Note 4 - Liquidity Risks and _2

Note 4 - Liquidity Risks and Management's Plans (Details Textual) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Net Income (Loss) Attributable to Parent, Total	$ (7,375)	$ (7,126)	$ (6,437)	$ (6,537)	$ (9,042)	$ (3,927)	$ (3,052)	$ (4,512)	$ (27,475)	$ (20,533)
Retained Earnings (Accumulated Deficit), Ending Balance	$ (685,122)				$ (657,647)				$ (685,122)	$ (657,647)

Note 5 - Accounting Policies _3

Note 5 - Accounting Policies and Recent Accounting Pronouncements (Details Textual) $ / shares in Units, shares in Thousands	Dec. 27, 2018USD ($)$ / shares	Jul. 02, 2018USD ($)	Dec. 31, 2018USD ($)shares	Mar. 31, 2017USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares	Jan. 01, 2019USD ($)	Feb. 28, 2018USD ($)	Dec. 31, 2017USD ($)	Nov. 01, 2017USD ($)
Number of Reporting Units					1
Goodwill, Impairment Loss					$ 0
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)					0
Foreign Currency Transaction Gain (Loss), before Tax, Total					500,000	$ 100,000
Marketable Securities, Realized Gain (Loss), Total					75,000	0
Asset Impairment Charges, Total					0	0
Liability for Contingent Milestone Payment, Noncurrent			$ 15,000,000		15,000,000	15,000,000
Preferred Stock Dividends, Income Statement Impact			$ 1,718,000	$ 3,600,000		$ 1,718,000
Preferred Stock, Discount on Shares									$ 4,500,000
Preferred Stock, Shares Remaining to Be Converted (in shares) | shares			0			0
Repayments of Convertible Debt						$ 1,500,000
Gain (Loss) on Extinguishment of Debt, Total					$ (1,794,000)	$ (3,345,000)
Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants (in shares) | shares					6,500	4,800
Number of Operating Segments					1
Intangible Assets, Net (Excluding Goodwill), Total			$ 77,100,000		$ 77,100,000	$ 77,100,000
Goodwill, Ending Balance			15,682,000		15,682,000	15,682,000
Operating Lease, Liability, Total					1,544,000
Operating Lease, Right-of-Use Asset					1,390,000
Accrued Liabilities, Current, Total			6,465,000		3,226,000	6,465,000
Other Liabilities, Noncurrent, Total			175,000			175,000
Marketable Securities, Unrealized Gain (Loss), Total					0	0
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total							$ 2,200,000
Operating Lease, Right-of-Use Asset							2,000,000
Accrued Liabilities, Current, Total							(72,000)
Other Liabilities, Noncurrent, Total							$ (139,000)
Conversion of Preferred Stock [Member]
Preferred Stock Dividends, Income Statement Impact						1,700,000
Panacea [Member] | Warrant Issued Related to Secured Convertible Promissory Note [Member]
Warrants and Rights Outstanding		$ 400,000
Panacea [Member] | Secured Convertible Promissory Note [Member]
Debt Instrument, Face Amount		1,500,000
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 400,000
Repayments of Convertible Debt	$ 1,500,000
Gain (Loss) on Extinguishment of Debt, Total	$ 400,000
Share Price (in dollars per share) | $ / shares	$ 15.33
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 12
Debt Instrument, Convertible, Number of Equity Instruments	125,000
Deerfield Loan [Member]
Liability for Contingent Milestone Payment, Noncurrent			$ 15,000,000		15,000,000	$ 15,000,000
Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member]
Liability for Contingent Milestone Payment, Noncurrent										$ 15,000,000
Headquarters [Member]
Security Deposit					140,000			$ 140,000	$ 225,000
Offices, Taipei, Taiwan [Member]
Security Deposit					$ 14,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)					3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)					10 years

Note 5 - Accounting Policies _4

Note 5 - Accounting Policies and Recent Accounting Pronouncements - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Indefinite intangible asset	$ 77,090	$ 77,090
Istaroxime Drug Candidate [Member]
Indefinite intangible asset	22,340
Rostafuroxin Drug Candidate [Member]
Indefinite intangible asset	$ 54,750

Note 6 - License Revenue with_3

Note 6 - License Revenue with Affiliate - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended						12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
License [Member]
License revenue with affiliate	$ 158	$ 40	$ 304	$ 159	$ 356	$ 204	$ 198	$ 1,023

Note 7 - Fair Value Measureme_3

Note 7 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
US Treasury Note [Member]
Available-for-sale marketable securities		$ 13,959
Fair Value, Inputs, Level 1 [Member] | US Treasury Note [Member]
Available-for-sale marketable securities		13,959
Fair Value, Inputs, Level 2 [Member] | US Treasury Note [Member]
Available-for-sale marketable securities
Fair Value, Inputs, Level 3 [Member] | US Treasury Note [Member]
Available-for-sale marketable securities
Fair Value, Recurring [Member]
Total Assets	$ 20,049	20,080
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total Assets	20,049	20,080
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total Assets
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Total Assets
Fair Value, Recurring [Member] | Money Market Funds [Member]
Cash equivalents	1,819	103
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	1,819	103
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents
Fair Value, Recurring [Member] | US Treasury Securities [Member]
Cash equivalents	18,230	6,018
Fair Value, Recurring [Member] | US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	18,230	6,018
Fair Value, Recurring [Member] | US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents
Fair Value, Recurring [Member] | US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents

Note 8 - Property and Equipme_3

Note 8 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Depreciation, Total	$ 195	$ 160

Note 8 - Property and Equipme_4

Note 8 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross	$ 7,172	$ 7,218
Accumulated depreciation and amortization	(6,374)	(6,416)
Property and equipment, net	798	802
Manufacturing, Laboratory, and Office Equipment [Member]
Property and equipment, gross	4,313	4,359
Furniture and Fixtures [Member]
Property and equipment, gross	390	390
Leasehold Improvements [Member]
Property and equipment, gross	$ 2,469	$ 2,469

Note 9 - Collaboration and De_3

Note 9 - Collaboration and Device Development Payable (Details Textual) $ / shares in Units, $ in Thousands	Dec. 21, 2018USD ($)$ / sharesshares	Dec. 07, 2018USD ($)$ / sharesshares	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 06, 2018USD ($)
Collaboration and Device Development Payable, Current			$ 1,972	$ 2,576
Gain (Loss) on Extinguishment of Debt, Total			(1,794)	$ (3,345)
Conversion of Battelle Payables [Member]
Gain (Loss) on Extinguishment of Debt, Total	$ (500)
Debt Conversion, Converted Instrument, Amount	1,500
Debt Conversion, Original Debt, Amount	$ 1,000
Private Placement [Member] | Series F Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	667,847
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 11.04
Warrants and Rights Outstanding, Term (Year)	1 year 180 days
Private Placement [Member] | Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	1,296,410
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 12.15
Warrants and Rights Outstanding, Term (Year)	5 years
Payment Restructuring of Battelle Payables [Member]
Collaboration and Device Development Payable, Interest Rate		6.00%
Collaboration and Device Development Payable, Repaid Payable Threshold to Qualify for Services on Credit		$ 3,000
Payments for Collaboration and Device Development Payable		1,000
Collaboration and Device Development Agreement, Aggregate Payments		$ 1,250
Collaboration and Device DevelopmentPayable, Number of Monthly Installments Payments Deferred		5
Collaboration and Device Development Payable, Periodic Payment, Total		$ 250
Royalty Guarantees, Commitments, Amount		$ 35,000			$ 25,000
Interest Payable, Current			$ 400
Payment Restructuring of Battelle Payables [Member] | Series E Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 19.50
Warrants and Rights Outstanding, Term (Year)		5 years
Common Stock Maximum Ownership Percentage For Warrant Exercise		9.99%
Payment Restructuring of Battelle Payables [Member] | Series E Warrants [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares		25,000
Payment Restructuring of Battelle Payables [Member] | Private Placement [Member]
Collaboration and Device Development Payable, Converted Payable Amount into Equity	$ 1,000
Sale of Stock, Number of Shares Issued in Transaction (in shares) | shares	100,607
Sale of Stock, Price Per Share (in dollars per share) | $ / shares	$ 9.9396
Payment Restructuring of Battelle Payables [Member] | Private Placement [Member] | Series F Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	17,103
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 11.04
Warrants and Rights Outstanding, Term (Year)	1 year 180 days
Payment Restructuring of Battelle Payables [Member] | Private Placement [Member] | Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	33,201
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 12.15
Warrants and Rights Outstanding, Term (Year)	5 years

Note 9 - Collaboration and De_4

Note 9 - Collaboration and Device Development Payable - Significant Input Assumptions of Warrant Valuation (Details) - Series E Warrants [Member]	Dec. 07, 2018
Measurement Input, Price Volatility [Member]
Measurement input	1.03
Measurement Input, Expected Term [Member]
Measurement input	5
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.027

Note 10 - Accrued Expenses - Ac

Note 10 - Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Research and development	$ 1,415	$ 2,361
Professional fees	543	2,473
Salaries, bonus & benefits	696	815
Manufacturing operations	183	212
Other	389	604
Total accrued expenses	$ 3,226	$ 6,465

Note 11 - Loan Payable - Curr_2

Note 11 - Loan Payable - Current Portion and Non-current Portion (Details Textual) - USD ($)	Mar. 20, 2020	Dec. 06, 2019	Oct. 24, 2019	Dec. 27, 2018	Dec. 21, 2018	Dec. 31, 2019	Apr. 30, 2019	Nov. 30, 2018	Oct. 30, 2018	Sep. 30, 2018	Apr. 30, 2018	Mar. 31, 2018	Jan. 31, 2018	Sep. 30, 2017	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Oct. 28, 2019	May 30, 2019	Dec. 05, 2018	Nov. 19, 2018	Nov. 16, 2018	Nov. 02, 2018	Oct. 19, 2018	Sep. 27, 2018	Sep. 12, 2018	Aug. 29, 2018	Aug. 14, 2018	Sep. 30, 2016
Gain (Loss) on Extinguishment of Debt, Total																$ (1,794,000)	$ (3,345,000)
Proceeds from Short-term Debt, Total																1,000,000	6,160,000
Repayments of Short-term Debt, Total																2,063,000	160,000
Loans Payable, Noncurrent, Total						$ 4,608,000										$ 4,608,000
Series I Warrants Issued with Conversion of Lee's International Debt [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)																162,804
Shares Issued, Price Per Share (in dollars per share)						$ 12.09										$ 12.09
Warrants and Rights Outstanding, Term (Year)						5 years										5 years
CVie Investments [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Total					$ 2,590,000
Loan Payable Obligation Converted to LPH II [Member]
Debt Conversion, Original Debt, Amount					6,000,000
First Quarter 2018 Loans Converted to LPH II [Member]
Debt Conversion, Original Debt, Amount					2,500,000
Third and Fourth Quarter 2018 Loans Converted to LPH II [Member]
Debt Conversion, Original Debt, Amount					3,500,000
Conversion of Loan Payable as Part of Private Placement Financing [Member]
Debt Conversion, Original Debt, Amount		$ 2,950,000				$ 2,950,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)																325,607
Shares Issued, Price Per Share (in dollars per share)						$ 9.06										$ 9.06
LPH II [Member]
Debt Instrument Requirement For Minimum Amount Rise																	$ 30,000,000
LPH [Member]
Proceeds from Issuance of Debt												$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage																	6.00%
Debt Instrument, Face Amount																				$ 600,000	$ 350,000		$ 500,000	$ 430,000	$ 500,000	$ 500,000	$ 480,000	$ 300,000
Gain (Loss) on Extinguishment of Debt, Total					(3,200,000)
Repayments of Debt				$ 160,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total				$ 182,000
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Percent of Pledged Deposits Required														110.00%
Loans Payable, Noncurrent, Total						$ 4,600,000										$ 4,600,000
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | Taipei Interbank Offer Rate (TAIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate														0.91%
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | CVie Investments [Member]
Line of Credit Facility, Maximum Borrowing Capacity														$ 5,800,000															$ 2,900,000
O-Bank Co., Ltd. [Member] | Nonrevolving Credit Facility [Member] | Subsequent Event [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 5,000,000
Debt Instrument, Term (Month)	2 years
O-Bank Co., Ltd. [Member] | Nonrevolving Credit Facility [Member] | Taipei Interbank Offer Rate (TAIBOR) [Member] | Subsequent Event [Member]
Debt Instrument, Basis Spread on Variable Rate	1.17%
O-Bank Co., Ltd. [Member] | CVie Investments [Member] | Revolving Credit Facility [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Total					$ 4,500,000							$ 3,500,000
LPH II Loan [Member] | LPH II [Member]
Proceeds from Issuance of Debt			$ 1,000,000
Debt Instrument, Interest Rate, Effective Percentage																		6.00%
Debt Payable to LPH II [Member]
Debt Instrument, Interest Rate, Stated Percentage																						4.00%
Debt Instrument, Face Amount																						$ 3,500,000
Gain (Loss) on Extinguishment of Debt, Total																(1,800,000)
Proceeds from Short-term Debt, Total								$ 2,500,000	$ 150,000	$ 300,000	$ 500,000
Repayments of Short-term Debt, Total							$ 50,000								$ 450,000
Interest Paid, Excluding Capitalized Interest, Operating Activities																127,000
Short-term Debt, Total						0										0
Loan payable to Bank Direct Capital Finance [Member]
Loans Payable to Bank, Total						$ 200,000										$ 200,000
Loan payable to Bank Direct Capital Finance [Member] | Loans Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage																			5.35%
Debt Instrument, Face Amount																			$ 700,000

Note 12 - Convertible Note Pa_3

Note 12 - Convertible Note Payable (Details Textual)	Dec. 27, 2018USD ($)$ / shares	Jul. 23, 2018USD ($)	Jul. 02, 2018USD ($)$ / sharesshares	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Proceeds from Convertible Debt					$ 1,500,000
Repayments of Convertible Debt					1,500,000
Gain (Loss) on Extinguishment of Debt, Total				$ (1,794,000)	$ (3,345,000)
Panacea [Member] | Secured Convertible Promissory Note [Member]
Debt Instrument, Face Amount			$ 1,500,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 12
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 400,000
Repayments of Convertible Debt	$ 1,500,000
Gain (Loss) on Extinguishment of Debt, Total	$ 400,000
Share Price (in dollars per share) | $ / shares	$ 15.33
Debt Instrument, Convertible, Number of Equity Instruments	125,000
Panacea [Member] | Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares			62,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 12
Class of Warrant or Right, Vesting Period (Month)			180 days
Warrants and Rights Outstanding, Term (Year)			5 years
Common Stock Maximum Ownership Percentage For Warrant Exercise			9.99%
Panacea [Member] | Series D Warrants [Member] | Warrant [Member]
Derivative Liability, Total			$ 400,000
Convertible Notes Payable [Member] | Panacea [Member]
Debt Instrument, Face Amount			1,500,000
Proceeds from Convertible Debt		$ 500,000	$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage			15.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 4
Debt Instrument, Convertible, Beneficial Conversion Feature			$ 400,000

Note 12 - Convertible Note Pa_4

Note 12 - Convertible Note Payable - Significant Input Assumptions of Warrant Valuation (Details) - Series D Warrants [Member]	Dec. 31, 2019
Measurement Input, Price Volatility [Member]
Measurement input	1.03
Measurement Input, Expected Term [Member]
Measurement input	5
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.0275

Note 13 - Restructured Debt L_3

Note 13 - Restructured Debt Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Nov. 01, 2017	Dec. 31, 2019	Dec. 31, 2018
Liability for Contingent Milestone Payment, Noncurrent		$ 15,000	$ 15,000
Deerfield Loan [Member]
Liability for Contingent Milestone Payment, Noncurrent		$ 15,000	$ 15,000
Deerfield Loan [Member] | Exchange and Termination Agreement [Member] | Deerfield Management, L.P. [Member]
Extinguishment of Debt, Amount	$ 25,000
Class of Warrant or Right, Number of Warrants Cancelled (in shares)	8,333
Class of Warrant or Right, Exercise Price of Cancelled Warrants (in dollars per share)	$ 2,360.40
Repayments of Long-term Debt, Total	$ 2,500
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations (in shares)	23,703
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding	2.00%
Liability for Contingent Milestone Payment, Noncurrent	$ 15,000

Note 13 - Restructured Debt L_4

Note 13 - Restructured Debt Liability - Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Restructured debt liability - contingent milestone payments	$ 15,000	$ 15,000
Deerfield Loan [Member]
Restructured debt liability - contingent milestone payments	$ 15,000	$ 15,000

Note 14 - Stockholders' Equit_2

Note 14 - Stockholders' Equity (Details Textual) - USD ($)	Dec. 06, 2019	Dec. 24, 2018	Dec. 21, 2018	Apr. 04, 2018	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Common Stock, Shares, Issued, Total (in shares)					13,697,420	13,697,420	10,711,088
Proceeds from Issuance of Private Placement						$ 22,982,000	$ 32,893,000
The 2011 Long-term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)					149,000	149,000	484,000
Series I Warrants Issued with Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,458,333
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 12.09
Warrants and Rights Outstanding, Term (Year)	5 years
Common Stock Maximum Ownership Percentage For Warrant Exercise	4.99%
Common Stock Maximum Ownership Percentage For Warrant Exercise, Per Each Holder	19.99%
Conversion of Loan Payable as Part of Private Placement Financing [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 9.06	$ 9.06
Debt Conversion, Original Debt, Amount	$ 2,950,000				$ 2,950,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,916,666
Shares Issued, Price Per Share (in dollars per share)	$ 9.06
Proceeds from Issuance of Common Stock	$ 26,400,000
Common Stock, Shares, Issued, Total (in shares)			3,928,513
Share Price (in dollars per share)			$ 9.9396
Proceeds from Issuance of Private Placement			$ 39,000,000
Private Placement [Member] | Lee’s Pharmaceutical Holdings Limited [Member]
Debt Conversion, Original Debt, Amount			6,000,000
Private Placement [Member] | Battelle [Member]
Debt Conversion, Original Debt, Amount			$ 1,000,000
Private Placement [Member] | LPH II [Member]
Stock Issued During Period, Shares, New Issues (in shares)				180,555
Shares Issued, Price Per Share (in dollars per share)				$ 14.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				45,139
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 16.56
Warrants and Rights Outstanding, Term (Year)				7 years
Private Placement, Purchase Price of Common Stock and Warrants				$ 2,600,000
Class of Warrant or Right, Vesting Period (Month)				180 days
Private Placement [Member] | Series F Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			667,847
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 11.04
Warrants and Rights Outstanding, Term (Year)			1 year 180 days
Private Placement [Member] | Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,296,410
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 12.15
Warrants and Rights Outstanding, Term (Year)			5 years
Private Placement [Member] | December 2018 Warrants [Member]
Common Stock Maximum Ownership Percentage For Warrant Exercise			9.99%

Note 14 - Stockholders' Equit_3

Note 14 - Stockholders' Equity - Common Shares Reserved for Future Issuance (Details) - $ / shares shares in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Common stock, capital shares reserved for future issuance (in shares)		4,741	3,283
Investors - December 2019 Financing [Member]
Common stock, capital shares reserved for future issuance (in shares)		1,458
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 12.09
Expiration date		12/06/24
Investors - Aerosurf [Member]
Common stock, capital shares reserved for future issuance (in shares)		988	988
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)
Expiration date		02/14/24
Investors - December 2018 Financing - Long-term [Member]
Common stock, capital shares reserved for future issuance (in shares)		1,296	1,296
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 12.15
Expiration date		12/04/23
Investors - December 2018 Financing - Short-term [Member]
Common stock, capital shares reserved for future issuance (in shares)		668	668
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 11.04
Expiration date		06/24/20
Battelle - 2018 Payables Restructuring Agreement [Member]
Common stock, capital shares reserved for future issuance (in shares)	[1]	25	25
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	[1]	$ 19.50
Expiration date	[1]	12/07/23
Panacea Venture Management Company Ltd. [Member]
Common stock, capital shares reserved for future issuance (in shares)		63	63
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 12
Expiration date		07/02/23
LPH II Investments Limited [Member]
Common stock, capital shares reserved for future issuance (in shares)		45	45
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 16.56
Expiration date		04/04/25
Investors - February 2017 Financing [Member]
Common stock, capital shares reserved for future issuance (in shares)		117	117
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 82.20
Expiration date		02/15/24
Investors - July 2015 Financing [Member]
Common stock, capital shares reserved for future issuance (in shares)		80	80
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 588
Expiration date		07/22/22
Battelle 2014 Collaboration Agreement [Member]
Common stock, capital shares reserved for future issuance (in shares)		1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 4,200
Expiration date		10/10/24
[1]	See, - Note 16 - Collaboration, Licensing and Research Funding Agreements, for further details on the Battelle collaboration agreement.

Note 15 - Stock Options and S_3

Note 15 - Stock Options and Stock-based Employee Compensation (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Feb. 01, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 10.02		$ 10.17
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total		$ 6,721	$ 1,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		5,600		$ 600
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 10,700
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 328 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 11.85		$ 12.66
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		$ 0
Chief Executive Officer [Member] | Non-plan Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
The 2011 Long-term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		2,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		149	484	484
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years

Note 15 - Stock Options and S_4

Note 15 - Stock Options and Stock-based Employee Compensation - Stock Options and Restricted Stock Units (RSUs) Outstanding and Available for Future Issuance (Details) - shares shares in Thousands	Dec. 31, 2019	Dec. 31, 2018
2011 Plan (in shares)	1,807	1,522
The 2011 Long-term Incentive Plan [Member]
2011 Plan (in shares)	1,804	1,519
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	149	484
Non-Plan [Member]
2011 Plan (in shares)	3	3

Note 15 - Stock Options and S_5

Note 15 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Shares Outstanding, Beginning Balance (in shares) | shares	1,472
Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share) | $ / shares	$ 20.19
Shares Granted (in shares) | shares	382
Weighted Average Exercise Price, Granted (in dollars per share) | $ / shares	$ 9.99
Shares Forfeited or Expired (in shares) | shares	(82)
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) | $ / shares	$ 40.74
Shares Outstanding, Ending Balance (in shares) | shares	1,772
Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share) | $ / shares	$ 17.61
Weighted Average Remaining Contractual Life, Outstanding (Year)	9 years
Shares Vested and Exercisable (in shares) | shares	521
Weighted Average Exercise Price, Vested and Exercisable (in dollars per share) | $ / shares	$ 29.34
Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)	8 years 328 days
Vested and expected to vest (in shares) | shares	1,692
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share) | $ / shares	$ 17.55
Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)	9 years

Note 15 - Stock Options and S_6

Note 15 - Stock Options and Stock-based Employee Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Unvested, Beginning Balance (in shares)	50
Unvested, Beginning Balance (in dollars per share)	$ 12.87
Awarded (in shares)	83
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 11.85	$ 12.66
Cancelled (in shares)	(48)
Cancelled (in dollars per share)	$ 12.99
Vested (in shares)	(50)
Vested (in dollars per share)	$ 12.87
Unvested, Ending Balance (in shares)	35	50
Unvested, Ending Balance (in dollars per share)	$ 11.85	$ 12.87

Note 15 - Stock Options and S_7

Note 15 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock-based compensation expense	$ 6,721	$ 955
Research and Development Expense [Member]
Stock-based compensation expense	1,932	232
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 4,789	$ 723

Note 15 - Stock Options and S_8

Note 15 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Weighted average expected volatility	95.00%	93.00%
Weighted average expected term (Year)	6 years 219 days	7 years
Weighted average risk-free interest rate	2.60%	2.70%
Expected dividends

Note 16 - Collaboration, Lice_2

Note 16 - Collaboration, Licensing and Research Funding Agreements (Details Textual) € in Millions	Nov. 01, 2017USD ($)	Aug. 31, 2017USD ($)	Jun. 30, 2017USD ($)	Oct. 31, 2014USD ($)	Oct. 31, 2017USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2018USD ($)	Dec. 31, 2012USD ($)
Proceeds from Short-term Debt, Total						$ 1,000,000		$ 6,160,000
LPH [Member] | Acquisition of Windtree [Member]
Business Combination, Consideration Transferred, Total	$ 10,000,000
Maximum [Member] | Lee's [Member] | Lee's Loan to Support Operations [Member]
Proceeds from Short-term Debt, Total					$ 3,900,000
License Agreement With Lee’s [Member]
Proceeds from License Fees Received			$ 1,000,000			1,000,000
License Agreement, Contingent Receivable, Maximum		$ 35,800,000	$ 37,500,000
Fair Value of Royalties and Milestones Foregone						300,000
Revenue, Remaining Performance Obligation, Amount						1,300,000
Philip Morris Products S.A. - License Agreement [Member]
Deferred Royalty Expense						400,000		$ 400,000
Johnson and Johnson - License Agreement [Member]
Potential License Fee Payable						2,500,000
Payment of License Cost Subject to Regulatory Approval						$ 1,000,000			$ 500,000
Percent of Cash Upfront and Milestone Fees Payable to Esteve						10.00%
Maximum Aggregate Cash Upfront and Milestone Fees Payable to Esteve						$ 20,000,000
Universita Degli Studi Do Miano-Biocca [Member]
Payment of License Cost for New Compounds Modulating						100,000	€ 0.1
Payment of License Cost Upon Obtaining Marketing Authorization						1,700,000	1.5
Payment of License Cost, Aggregation Fund						200,000	€ 0.2
Battelle Applies [Member]
Maximum Royalty Paid on Completion of Activities Under the Agreement				$ 25,000,000		$ 35,000,000

Note 17 - Related Party Trans_2

Note 17 - Related Party Transactions (Details Textual) - USD ($)	Dec. 06, 2019	Dec. 31, 2019	Dec. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Dec. 31, 2018
Conversion of Loan Payable as Part of Private Placement Financing [Member]
Debt Conversion, Original Debt, Amount	$ 2,950,000	$ 2,950,000
Affiliate of Lee’s [Member] | Private Placement in a related Party Transaction [Member]
Related Party Transaction, Amounts of Transaction					$ 2,600,000
Affiliate of Lee’s [Member] | Converting Existing Loans Payable [Member]
Related Party Transaction, Amounts of Transaction			$ 6,000,000
Lee’s Pharmaceutical Holdings Limited [Member]
Due to Related Parties, Total		500,000	$ 500,000			$ 500,000
Lee’s Pharmaceutical Holdings Limited [Member] | Bank Credit Facility is Guaranteed [Member]
Related Party Transaction, Amounts of Transaction						$ 4,600,000
Lee’s Pharmaceutical Holdings Limited [Member] | Purchase of KL4 Surfactant Raw Materials on Behalf of Lee's [Member]
Due from Related Parties, Total		$ 800,000
Affiliate of Panacea [Member] | Secured Convertible Promissory Note [Member]
Related Party Transaction, Amounts of Transaction				$ 1,500,000
Rui Jin (HK) Consulting Management Company Limited, an Affiliate of Panacea [Member]
Related Party Transaction, Shares Issued (in shares)		32,143				38,138
Lee’s Pharmaceutical Holdings Limited [Member] | Windtree Therapeutics [Member]
Ownership Percentage		35.00%	40.00%			40.00%
Lee’s Pharmaceutical Holdings Limited [Member] | CVie Investment [Member]
Ownership Percentage			49.00%			49.00%
KPCB [Member] | Windtree Therapeutics [Member]
Ownership Percentage		11.00%	14.00%			14.00%
KPCB [Member] | CVie [Member]
Ownership Percentage			27.00%			27.00%
Panacea [Member] | Windtree Therapeutics [Member]
Ownership Percentage		15.00%

Note 20 - Income Taxes (Details

Note 20 - Income Taxes (Details Textual) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards, Total	$ 618.9	$ 606.6
Operating Loss Carryforwards Not Subject to Expiration	35.9
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	597.1	584.8
State and Local Jurisdiction [Member] | Pennsylvania [Member]
Operating Loss Carryforwards, Total	582.7
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	16.9	16.7
Orphan Drug Tax Credit [Member]
Tax Credit Carryforward, Amount	$ 0.1	$ 0.1

Note 20 - Income Taxes - Income

Note 20 - Income Taxes - Income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income tax benefit, statutory rates	$ (5,770)	$ (4,312)
State taxes on income, net of federal benefit	(1,182)	(535)
Impact of tax reform		5
Research and development tax credit	(934)	(351)
Foreign rate differential	22	24
Employee related and other	1,983	2,875
Interest related	79	186
Income tax expense / (benefit), statutory rates	(5,802)	(2,108)
Valuation allowance	5,802	2,108
Income tax benefit, net

Note 20 - Income Taxes - Deferr

Note 20 - Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Net operating loss carryforwards (federal and state)	$ 180,979	$ 176,759
Research and development tax credit	17,599	16,718
Compensation expense on stock	2,142	1,121
Charitable contribution carryforward
Other accrued	934	1,016
Deferred revenue		57
Depreciation	128	309
Total long-term deferred tax assets	201,782	195,980
IPRD	(15,419)	(15,476)
Total long-term deferred tax liabilities	(15,419)	(15,476)
Valuation allowance	(201,782)	(195,980)
Deferred tax liabilities, net	$ (15,419)	$ (15,476)

Note 21 - Leases (Details Textu

Note 21 - Leases (Details Textual)	12 Months Ended
	Dec. 31, 2018USD ($)ft²	Dec. 31, 2019USD ($)	Apr. 30, 2019ft²	Feb. 28, 2018USD ($)ft²	Dec. 31, 2017USD ($)ft²
Operating Lease, Liability, Total		$ 1,544,000
Operating Leases, Rent Expense, Total	$ 800,000
Headquarters [Member]
Area of Real Estate Property (Square Foot) | ft²				21,189	30,506
Security Deposit		140,000		$ 140,000	$ 225,000
Offices, Taipei, Taiwan [Member]
Area of Real Estate Property (Square Foot) | ft²	2,635		1,317
Security Deposit		$ 14,000

Note 21 - Leases - Lease Costs

Note 21 - Leases - Lease Costs (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Operating lease cost	$ 889
Variable lease cost	22
Total lease cost	911
Operating cash flows used for operating leases	951
Operating lease liabilities arising from obtaining right-of-use assets	$ 364
Weighted average remaining lease term (in years) (Year)	2 years 73 days
Weighted average incremental borrowing rate	9.00%

Note 21 - Leases - Future Minim

Note 21 - Leases - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2019USD ($)
2020	$ 850
2021	640
2022	180
2023	23
Thereafter
Total lease payments	1,693
Less imputed interest	(149)
Total operating lease liabilities at December 31, 2019	$ 1,544

Note 22 - Selected Quarterly _3

Note 22 - Selected Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Details) - USD ($) $ / shares in Units, shares in Thousands	3 Months Ended									12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2019	Dec. 31, 2018
Total revenues			$ 158,000	$ 40,000	$ 304,000	$ 229,000	$ 1,051,000	$ 204,000		$ 198,000	$ 1,788,000
Research and development	$ 2,140,000	$ 3,792,000	3,413,000	3,342,000	2,368,000	2,197,000	2,879,000	3,118,000		12,687,000	10,562,000
Selling, general and administrative	2,414,000	3,395,000	3,240,000	3,355,000	2,787,000	1,500,000	1,208,000	1,926,000		12,404,000	7,421,000
Total expenses	4,554,000	7,187,000	6,653,000	6,697,000	5,155,000	3,697,000	4,087,000	5,044,000		25,091,000	17,983,000
Operating loss	(4,554,000)	(7,187,000)	(6,495,000)	(6,657,000)	(4,851,000)	(3,468,000)	(3,036,000)	(4,840,000)		(24,893,000)	(16,195,000)
Other income / (expense), net	(2,821,000)	61,000	58,000	120,000	(4,191,000)	(459,000)	(16,000)	328,000		(2,582,000)	(4,338,000)
Net Income (Loss) Attributable to Parent, Total	$ (7,375,000)	$ (7,126,000)	$ (6,437,000)	$ (6,537,000)	$ (9,042,000)	$ (3,927,000)	$ (3,052,000)	$ (4,512,000)		$ (27,475,000)	$ (20,533,000)
Net loss per common share Basic and diluted (in dollars per share)	$ (0.64)	$ (0.66)	$ (0.60)	$ (0.61)	$ (9.71)	$ (3.13)	$ (2.44)	$ (4.19)		$ (2.51)	$ (23.20)
Weighted average number of common shares outstanding Basic and diluted (in shares)	11,532	10,730	10,730	10,714	2,397	1,256	1,250	1,076		10,928	1,498
Grant revenue						$ 70,000	$ 695,000				$ 765,000
AEROSURF warrant dividend					$ (12,505,000)						(12,505,000)
Deemed dividend on preferred stock					(1,718,000)				$ (3,600,000)		(1,718,000)
Net (loss) / income attributable to common shareholders					(23,265,000)	(3,927,000)	(3,052,000)	$ (4,512,000)		(27,475,000)	(34,756,000)
License [Member]
License revenue with affiliate			$ 158,000	$ 40,000	$ 304,000	$ 159,000	$ 356,000	$ 204,000		$ 198,000	$ 1,023,000

Note 23 - Subsequent Events (De

Note 23 - Subsequent Events (Details Textual) - USD ($)	Mar. 20, 2020	Mar. 18, 2020	Sep. 30, 2017	Dec. 31, 2019	Dec. 31, 2018
Loans Payable, Noncurrent, Total				$ 4,608,000
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member]
Loans Payable, Noncurrent, Total				$ 4,600,000
O-Bank Co., Ltd. [Member] | Revolving Credit Facility [Member] | Taipei Interbank Offer Rate (TAIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate			0.91%
Subsequent Event [Member] | O-Bank Co., Ltd. [Member] | Nonrevolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 5,000,000
Debt Instrument, Term (Month)	2 years
Subsequent Event [Member] | O-Bank Co., Ltd. [Member] | Nonrevolving Credit Facility [Member] | Taipei Interbank Offer Rate (TAIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	1.17%
AEROSURF Funding Term Sheet [Member] | Subsequent Event [Member] | Lee’s Pharmaceutical Holdings Limited [Member]
Nonrefundable Payments, Tranche One		$ 1,000,000
Nonrefundable Payments, Tranche Two		1,400,000
Nonrefundable Payments, Tranche Three		1,500,000
Nonrefundable Payments, Last Payment, Subject to Adjustment		400,000
Minimum Proceeds from Sale of Equity Securities		$ 4,500,000
Percentage of Amount Funded for Development, Repaid		125.00%
Percentage of Revenue, Pay to Counter Party		50.00%